**Positive Phase 3 results from the INTerpath-001 trial of Moderna and Merck’s personalized mRNA cancer vaccine intismeran autogene (mRNA-4157/V940) plus pembrolizumab form the main driver of trader sentiment.** Announced in mid-August 2026, the data showed statistically significant improvements in recurrence-free survival and distant metastasis-free survival versus Keytruda alone in over 1,100 patients with resected high-risk stage IIB–IV cutaneous melanoma—the first successful late-stage readout for an individualized neoantigen therapy or mRNA-based cancer vaccine. Merck and Moderna have stated plans to present full results at an upcoming medical meeting and begin regulatory discussions, positioning a BLA filing for late 2026 or early 2027. Breakthrough therapy designation and the companies’ prior Phase 2 durability data (49% risk reduction at five years) support an accelerated path, though actual submission timing hinges on data maturity, FDA feedback, and manufacturing readiness for the personalized platform. Other candidates, such as Replimune’s RP1, face separate regulatory hurdles and do not directly compete in this market.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于$44,260 交易量
2027-06-30
2027年3月31日
47%
2027年6月30日？
88%
$44,260 交易量
2027年3月31日
$3,659 交易量
47%
2027年6月30日？
$40,601 交易量
88%
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by March 31, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No".
Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication.
A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof.
The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify.
If the FDA grants approval of intismeran autogene on or before March 31, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed.
The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No".
Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication.
A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof.
The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify.
If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed.
The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.**Positive Phase 3 results from the INTerpath-001 trial of Moderna and Merck’s personalized mRNA cancer vaccine intismeran autogene (mRNA-4157/V940) plus pembrolizumab form the main driver of trader sentiment.** Announced in mid-August 2026, the data showed statistically significant improvements in recurrence-free survival and distant metastasis-free survival versus Keytruda alone in over 1,100 patients with resected high-risk stage IIB–IV cutaneous melanoma—the first successful late-stage readout for an individualized neoantigen therapy or mRNA-based cancer vaccine.
Merck and Moderna have stated plans to present full results at an upcoming medical meeting and begin regulatory discussions, positioning a BLA filing for late 2026 or early 2027. Breakthrough therapy designation and the companies’ prior Phase 2 durability data (49% risk reduction at five years) support an accelerated path, though actual submission timing hinges on data maturity, FDA feedback, and manufacturing readiness for the personalized platform. Other candidates, such as Replimune’s RP1, face separate regulatory hurdles and do not directly compete in this market.
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by March 31, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No".
Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication.
A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof.
The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify.
If the FDA grants approval of intismeran autogene on or before March 31, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed.
The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.
Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication.
A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof.
The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify.
If the FDA grants approval of intismeran autogene on or before March 31, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed.
The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.
市场开放时间： Aug 31, 2026, 11:11 AM ET
交易量
$44,260结束日期
2027-07-01市场开放时间
Aug 31, 2026, 11:11 AM ETThis market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by March 31, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No".
Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication.
A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof.
The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify.
If the FDA grants approval of intismeran autogene on or before March 31, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed.
The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No".
Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication.
A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof.
The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify.
If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed.
The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.**Positive Phase 3 results from the INTerpath-001 trial of Moderna and Merck’s personalized mRNA cancer vaccine intismeran autogene (mRNA-4157/V940) plus pembrolizumab form the main driver of trader sentiment.** Announced in mid-August 2026, the data showed statistically significant improvements in recurrence-free survival and distant metastasis-free survival versus Keytruda alone in over 1,100 patients with resected high-risk stage IIB–IV cutaneous melanoma—the first successful late-stage readout for an individualized neoantigen therapy or mRNA-based cancer vaccine.
Merck and Moderna have stated plans to present full results at an upcoming medical meeting and begin regulatory discussions, positioning a BLA filing for late 2026 or early 2027. Breakthrough therapy designation and the companies’ prior Phase 2 durability data (49% risk reduction at five years) support an accelerated path, though actual submission timing hinges on data maturity, FDA feedback, and manufacturing readiness for the personalized platform. Other candidates, such as Replimune’s RP1, face separate regulatory hurdles and do not directly compete in this market.
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by March 31, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No".
Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication.
A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof.
The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify.
If the FDA grants approval of intismeran autogene on or before March 31, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed.
The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.
Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication.
A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof.
The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify.
If the FDA grants approval of intismeran autogene on or before March 31, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed.
The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.
交易量
$44,260结束日期
2027-07-01市场开放时间
Aug 31, 2026, 11:11 AM ET**Positive Phase 3 results from the INTerpath-001 trial of Moderna and Merck’s personalized mRNA cancer vaccine intismeran autogene (mRNA-4157/V940) plus pembrolizumab form the main driver of trader sentiment.** Announced in mid-August 2026, the data showed statistically significant improvements in recurrence-free survival and distant metastasis-free survival versus Keytruda alone in over 1,100 patients with resected high-risk stage IIB–IV cutaneous melanoma—the first successful late-stage readout for an individualized neoantigen therapy or mRNA-based cancer vaccine. Merck and Moderna have stated plans to present full results at an upcoming medical meeting and begin regulatory discussions, positioning a BLA filing for late 2026 or early 2027. Breakthrough therapy designation and the companies’ prior Phase 2 durability data (49% risk reduction at five years) support an accelerated path, though actual submission timing hinges on data maturity, FDA feedback, and manufacturing readiness for the personalized platform. Other candidates, such as Replimune’s RP1, face separate regulatory hurdles and do not directly compete in this market.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题